Corporate presentation scheduled for Tuesday, 04 June 2024 at 4:00 PM
PT
SAN DIEGO and SEOUL, South Korea, May
23, 2024 /PRNewswire/ -- Bionoxx Inc., an innovative biotech
company developing neutrophil-directed T cell modulation
technology, announced today it will unveil its novel
immunomodulatory technology at the upcoming 2024 BIO International
Convention.
Bionoxx research has discovered that cancer patients exhibit
impaired neutrophil homeostatic dynamics in their peripheral blood,
a condition that may significantly contribute to T cell dysfunction
and suboptimal clinical outcomes in these individuals. BNX has
pioneered the BNX-IFS, a novel technology aimed at identifying
activated neutrophils linked to T cell homeostasis within
circulating immune cells. Bionoxx has already received clearance of
an Investigational New Drug (IND) application by the United States
Food and Drug Administration (FDA) to initiate a first-in-human
clinical study of mOTS-412 or mOTS-412/anti-PD-L1 combination in
participants with immune checkpoint inhibitor-resistant solid
tumors. The trial is expected to begin in the latter half of 2024
in the United States.
"FDA's acceptance of our IND application is a significant
milestone for the development of our immunomodulatory pipeline and
an opportunity to refine and validate the pioneering BNX-IFS
technology." said Dr. Tae-Ho Hwang,
CTO at Bionoxx Inc. " BNX-IFS represents a promising new platform
that would enable generation of new treatment regimens for
immune-related diseases."
About Bionoxx Products
BNX-IFS (Bionoxx's Immune Function States) is a novel technology
that determines disease-related "immune dynamics" with circulating
immune cells. Especially, BNX-IFS revealed that neutrophil
plasticity may orchestrate T cell homeostasis. This has been
partially proven in nonclinical disease models and clinical
specimen from healthy as well as patients with immune-related
diseases. Bionoxx is developing BNX-IFS as a tool for personalized
immune modulation by optimizing T cell homeostasis in a variety of
immune-mediated diseases.
OTS-412 is an investigational oncolytic virus designed to work
with Bionoxx's immunomodulatory approach to destroy cancer cells.
The immunomodulatory approach enhanced cancer-specific cytotoxic T
cell immunity and induced synergistic anti-tumor effect with ICI in
ICI-resistant nonclinical models.
About Bionoxx Inc.
Bionoxx Inc.(headquartered in South
Korea) is an innovative biotechnology company pioneering
neutrophil-directed T cell modulation to fight cancer and immune
disorders. We are dedicated to maximizing clinical outcome for
patients by tailoring immunotherapies with our novel technologies.
Bionoxx is avidly seeking partners and collaborators in discovery
and development efforts for cancer and immune-mediated diseases
(e.g., acute viral infection, autoimmune diseases). For more
information, please visit
https://www.linkedin.com/company/bionoxx.
View original
content:https://www.prnewswire.co.uk/news-releases/bionoxx-to-highlight-innovative-strategy-for-addressing-immune-related-diseases-at-2024-bio-international-conference-302152827.html